Registration of health products for human use: Niger Republic case (from January 2018 to December 2020)
Abstract
Objective: Our study aims to make a nomenclature of the pharmaceutical products having received an authorization of sale on the market (MA) in Niger Republic and to describe the profiles of the various applicant laboratories and or manufacturers. We had conducted a retrospective and descriptive study on new applications for registration of health products for human use examined in first intention only by the National Commission for Health Products Approval (NCHPA) from January 2018 to December 2020.
Material and methods: Over this period, 7 sessions of the NCHPA were held, including 3 in 2018, 2 in 2019, and 2 in 2020. In total, 951 dossiers for registration were reviewed in first intention.
Results: It was found that the majority of applicant laboratories (37.22%) as well as manufacturer laboratories (40.38%) were from India. The most represented therapeutic class was antibiotics (21.35%) followed by antimalarial (9.67%). However, the main route of administration was oral (79.28%) with a predominance of tablets (52.47%). Our study had also noted that only 10.10% of the dossiers have been accepted against 86.75% postponed due to lack of required information.
Summary ad conclusion: The national drug nomenclature remains the main document guiding the prescription and dispensing of products with a valid market authorization in the country. This is why all the actors in pharmaceutical logistics must have at hand all the information on the products approved in Niger.
Downloads
References
2. West African Economic and Monetary Union (UEMOA). Regulation n°04/2020/CM/UEMOA of 28th September 2020, relating to registration procedures for pharmaceutical products for human use in UEMOA member states; 2020 Sept.
3. Assissé-Nowoto MA. Management of the issuance of marketing authorizations (MA) for medicines for human use in Mali in 2019. Thesis of Pharmacy. University of Sciences, Techniques and Technologies of Bamako; 2019 N°12. p.107.
4. Ofirdan A. Approval of medicines for human use in Togo: year 2017. Thesis of Pharmacy. University of Lomé; 2017.
5. Mounkoro K. Evaluation of the registration process of medicines for human use in the Republic of Mali in 2013. Doctoral thesis in pharmacy. University of Sciences, Techniques and Technologies of Bamako; 2015 N°40.
6. Bakabe Mahamadou Roumanatou. “Evaluation of the availability and marketing of medicines after obtaining the marketing authorisation (MA) from the import and wholesale establishments of Bamako”. Thesis of Pharmacy, FMOS/FAPH of USTTB, Bamako; 2008. N°9.p. 82.
7. Kouamba G. A. Drug registration process in Mali: Case of antibiotics and antimalarials in 2016. Thesis of Pharmacy. University of Sciences, Techniques and Technologies of Bamako; 2018 N°40.
8. Coulibaly Ylombou Jeanine. "Evaluation of the respect and application of pharmaceutical regulation in Burkina Faso: the case of special import authorisations for pharmaceutical products". Thesis of Pharmacy, UFR/SDS; Ouagadougou; 2012 N°158.
9. Ministry of Health. Niger Health Statistics Yearbook [Internet]. 2017 [cited 2021 Nov 14]. Available from:
http://www.snis.cermes.net/wp-content/uploads/Annuaire_Statistiques_2017.pdf
10. Severe Malaria Observatory [Internet]. 2018 [cited 2021 Nov 2]. Available from:
https://www.severemalaria.org/fr/pays/niger
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM